| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03863587 Details | 2022-05-10 Interventional | 1 | 24 | Ramucirumab Healthy Male Vo… | The study was terminated prematurely due to the difficulty in recruiting participants caused by
the COVID-19 pandemic. - | |||
| NCT05365464 Details | 2022-05-09 Interventional | 2 | 0 | Progesterone Abortion, Habit… Abortion, Spont… Fetal Death Recurrence Recurrent Pregn… | Investigator still working on protocol and not sure when it will be ready - | |||
| NCT04544267 Details | 2022-05-09 Interventional | 3 | - | Vaccines Influenza, Huma… Influenza | Decision prompted due to COVID -19 pandemic challenges on:
1. Low influenza virus circulation rates on Pediatric population
2. Challenges on Recruitment/participant follow-up
3. Uncertainties on COVID-19 situation for 2022-2023 influenza season - | |||
| NCT04535102 Details | 2022-05-09 Interventional | 2 | 0 | Polatuzumab ved… Lymphoma Lymphoma, B-Cel… Lymphoma, Large… Diffuse Large B… | Lack of sufficient patient population - | |||
| NCT04131192 Details | 2022-05-06 Interventional | 1 | 13 | Gemcitabine Pancreatic Neop… Pancreatic Canc… | Combined with the analysis of the existing data of the trial, there was no obvious advantage
compared with the clinical standard treatments, and the clinical trial was decided to be
terminated based on the benefit of the subjects. - | |||
| NCT03795350 2017-005030-29 Details | 2022-05-06 Interventional | 1 | [1 Refs] | 19 | Beclomethasone Bromides Formoterol Fuma… Glycopyrrolate Lung Diseases, … Pulmonary Disea… Asthma Chronic Obstruc… | In light of the cessation of non-essential clinical activities at CPU due to the COVID-19
pandemic, the sponsor has determined to terminate the study early. - | ||
| NCT03655613 Details | 2022-05-06 Interventional | 1/2 | 20 | Nivolumab Carcinoma Carcinoma, Rena… Hepatocellular … Renal Cell Carc… | Study terminated due to administrative reasons. - | |||
| NCT03282669 Details | 2022-05-06 Interventional | 4 | [4 Refs] | 0 | Hydromorphone Morphine Pain, Postopera… Respiratory Ins… Obesity | Change in institutional policy. Change in resources available. - | ||
| NCT03041311 2017-000358-20 Details | 2022-05-06 Interventional | 2 | 107 | Atezolizumab Carboplatin Etoposide Lung Neoplasms Small Cell Lung… Small Cell Lung… | Primary Analysis and survival follow up completed per protocol. Not stopped due to safety
concerns. Limitation of the trial is small numbers of subjects, since it is a Phase 2 clinical trial. Small sample size may have reduced the ability to observe statistically significant treatment effects on secondary myelopreservation measures (i.e. occurrence of FN AEs, infections and antibiotics usage). | |||
| NCT04806945 Details | 2022-05-05 Interventional | 3 | 0 | Carboplatin Paclitaxel Uterine Cervica… Cervical Cancer | The sponsor terminated the trial. - | |||
| NCT04465734 Details | 2022-05-05 Interventional | 3 | 0 | Sorafenib Carcinoma Carcinoma, Hepa… Hepatocellular … | The trial used sorafenib as a control drug. It's not suitable now(after the A+T has been
approved).The sponsor terminated the trial. - | |||
| NCT03674827 Details | 2022-05-05 Interventional | 1 | 36 | Immunomodulatin… Breast Neoplasm… Carcinoma, Non-… Lung Neoplasms Triple Negative… Non-Small Cell … Triple-negative… | The study was terminated due to the review of the asset (VBIR-2) within the Sponsor's oncology
portfolio; the study was not terminated because of safety concerns. - | |||
| NCT05359874 Details | 2022-05-04 Interventional | 2 | 0 | Bevacizumab Breast Neoplasm… Breast Cancer | application has been withdrawn - | |||
| NCT05170789 Details | 2022-05-04 Interventional | 2 | [3 Refs] | 0 | Dexamethasone Elotuzumab Multiple Myelom… Neoplasms, Plas… Refractory Mult… Relapsed Multip… | The study collaborator -Karyopharm- is not doing Myeloma studies funding, so they let the study
investigators know they are not funding the study anymore. - | ||
| NCT03891264 Details | 2022-05-04 Interventional | 4 | 7 | Cannabidiol Back Pain Low Back Pain Neuroinflammato… Back Pain, Low | Funding obtained to do a larger placebo-controlled trial - | |||
| NCT03770455 Details | 2022-05-03 Interventional | 2 | 6 | Avelumab Prostatic Neopl… Metastatic Cast… | Early signs of progression and learned experience that the assumed time period between psa
progression and radiographic progression was shorter than expected Study did not reach target number of participants needed to reach target power for statistically reliable results due to poor recruitment during COIVD pandemic and early termination of study. Study closed early due to safety concerns regarding rapid clinical progression of several participants. | |||
| NCT03324282 Details | 2022-05-03 Interventional | 2 | 65 | Avelumab Carcinoma Urinary Bladder… Bladder Carcino… | ANSM's refusal to validate ATU requests for avelumab in bladder cancer, Decrease in
recruitment, Most investigators would like to offer avelumab for maintenance, Absence of
benefit to the chemo-immuno combination (pembro+gem-platinum) in phase III - | |||
| NCT03172936 2017-000707-25 Details | 2022-05-03 Interventional | 1 | 106 | Spartalizumab Lymphoma Solid Tumors an… | Sponsor's decision - | |||
| NCT00124891 Details | 2022-05-03 Interventional | 2 | - | Anti-Arrhythmia… Arrhythmias, Ca… Tachycardia Tachycardia, Ve… Arrhythmias | - - | |||
| NCT04492254 2020-003125-39 Details | 2022-05-02 Interventional | 3 | 219 | Enoxaparin COVID-19 | Average event rate (end point) was much lower than expected. A larger sample size would have
been required to maintain same statistical power, which was not achievable in a feasible time
scale. No safety concerns were identified with bleeding. - |